Latest news with #ZevraTherapeutics
Yahoo
2 days ago
- Business
- Yahoo
Those who invested in Zevra Therapeutics (NASDAQ:ZVRA) three years ago are up 102%
Explore Zevra Therapeutics's Fair Values from the Community and select yours The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For example, the Zevra Therapeutics, Inc. (NASDAQ:ZVRA) share price has soared 102% in the last three years. That sort of return is as solid as granite. It's also good to see the share price up 53% over the last quarter. So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Given that Zevra Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. In the last 3 years Zevra Therapeutics saw its revenue grow at 36% per year. That's well above most pre-profit companies. Meanwhile, the share price performance has been pretty solid at 26% compound over three years. This suggests the market has recognized the progress the business has made, at least to a significant degree. Nonetheless, we'd say Zevra Therapeutics is still worth investigating - successful businesses can often keep growing for long periods. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. A Different Perspective It's nice to see that Zevra Therapeutics shareholders have received a total shareholder return of 77% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 1.7% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the 'Events & Presentations' page in the Investor Relations section of Zevra's website at To join via telephone, please use the following dial-in information: (800) 245-3047 (United States) +1 (203) 518-9765 (International) Conference ID: ZVRAQ225 A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the 'Events & Presentations' page of Zevra's website at About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit or follow us on X and LinkedIn. Caution Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra's participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra's other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-07-2025
- Business
- Yahoo
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
For Immediate Release Chicago, IL – July 17, 2025 – Today, Zacks Equity Research discusses Catalyst Pharmaceuticals CPRX, Zevra Therapeutics ZVRA, Theravance Biopharma TBPH, Aldeyra Therapeutics ALDX and Larimar Therapeutics LRMR. Industry: Small Drugs Link: The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again threatened to impose heavy tariffs, as high as 200%, on pharmaceutical imports. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at encouraging American pharmaceutical companies to shift their production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are imposed. However, despite the threat of a 200% tariff, the biotech sector remained stable. The delay brings relief for the sector. Moreover, most global pharma companies have already committed to investing in boosting domestic manufacturing. Amid the tariff headwinds, the Zacks Medical-Drugs industry is showing promising trends backed by positive pipeline and regulatory developments. Innovation is at its peak with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention. M&A activity also remains healthy. These factors should continue to drive stocks like Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics. Industry Description The Zacks Medical-Drugs industry comprises small and some medium-sized drug companies that make medicines for both human and veterinary use. We have a separate industry outlook discussion on big drugmakers. Small drugmakers have a limited portfolio of marketed drugs or no commercial-stage drugs at all. Some drugmakers are dependent on just one marketed drug or pipeline candidate. For such companies, upfront or milestone payments from collaboration partners — in most cases, their larger counterparts — are the main sources of revenues. These companies need ample free cash flow to fund their R&D activities. Factors Shaping the Future of the Medical-Drugs Industry The success or failure of key pipeline candidates in clinical studies can significantly drive the stock price of industry players. Successful innovation and product line extensions in important therapeutic areas and strong clinical study results may act as important catalysts for the stocks. These companies regularly seek external partners and collaborators for complementary strengths. A partnership deal with a popular drugmaker is a good sign about the potential of small pharma companies, especially when an equity investment is included in the deal. M&A deals are in full swing in the sector, signaling growth. For smaller companies, succeeding in a shifting global market and evolving healthcare landscape requires adopting innovative business models, investing in new technologies and increasing investments in personalized medicines. Over the past few years, scientific and technological advancements have made it possible to develop personalized therapies. Other than that, adoption and information exchange through the meaningful use of health IT, development of therapies that improve overall patient outcomes and investment in developing and emerging markets are some of the key priorities for drug companies. Artificial intelligence and machine learning techniques are being used for the rapid advancement of drug discovery and target identification processes. The smaller companies have their share of risk in the form of unstable cash flows. Also, the failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be huge setbacks for these smaller companies and significantly hurt their share prices. Zacks Industry Rank Indicates Bright Prospects The group's Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks. The Zacks Medical-Drugs industry currently carries a Zacks Industry Rank #96, which places it in the top 39% of the 245 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present you with a few top-ranked stocks to capitalize on the thriving prospects of the small and medium-sized drugmakers' space, let's take a look at the industry's recent stock-market performance and the valuation picture. Industry Versus S&P 500 and Sector The Zacks Medical-Drugs industry is a huge 155-stock group within the broader Medical sector. The industry has outperformed the Zacks Medical sector while slightly underperforming the S&P 500 so far this year. Stocks in this industry have collectively risen 5.6% year to date against the Zacks Medical sector's decrease of 2.9%. The Zacks S&P 500 composite has risen 6.9% in the said time frame. Industry's Current Valuation Based on the trailing 12 months price-to-sales ratio (P/S TTM), which is a commonly used multiple for valuing these small drugmakers, the industry is currently trading at 2.32, compared with the S&P 500's 5.66 and the Zacks Medical sector's 2.37. Over the last five years, the industry has traded as high as 3.56, as low as 1.93 and at the median of 2.42, as the chart below shows. 5 Drug Stocks to Bet On Catalyst Pharmaceuticals: Coral Gables, FL-based Catalyst Pharmaceuticals' lead drug is Firdapse, which is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS), an ultra-rare disease. The drug has been witnessing strong demand driven by increasing prescription rates and new patient starts. In January 2025, Catalyst settled Firdapse patent litigation with Teva, protecting the drug's exclusivity in the United States till Feb. 25, 2035. Agamree, its newest acquired muscle disorder drug, was launched in the U.S. market in 2024. With Agamree's approval and launch, Catalyst has further diversified its commercial portfolio. The stock of Catalyst Pharmaceuticals has risen 0.4% so far this year. The consensus estimate for 2025 earnings has risen from $2.23 per share to $2.25 per share over the past 60 days. The company has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Theravance Biopharma: Cayman Islands-based Theravance Biopharma generates revenues in the United States from its collaboration with Viatris related to the sales of Yupelri, a nebulized therapy for chronic obstructive pulmonary disease. The product has been witnessing a strong sales uptake owing to increased customer demand, resulting in increased collaboration revenues for Theravance. The company's ongoing restructuring initiatives are saving costs. Theravance is currently focusing on developing its pipeline candidate, ampreloxetine, a norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy in the phase III CYPRESS study. The CYPRESS study is expected to complete patient enrollment by late summer of 2025. Top-line data from the same is expected six months after enrollment is completed. The stock of Theravance Biopharma has risen 22.6% so far this year. The consensus estimate for 2025 earnings has declined from 3 cents per share to 1 cent per share over the past 60 days. The company has a Zacks Rank #2. Larimar Therapeutics: CA-based Larimar Therapeutics is a clinical-stage company making medicines for rare diseases. Its lead pipeline candidate is nomlabofusp (CTI-1601), being developed as a potential treatment for Friedreich's ataxia (FA). Larimar Therapeutics plans to file a biologics license application seeking accelerated approval of nomlabofusp for FA in the second quarter of 2026. Larimar plans to expand the nomlabofusp clinical program to patients around the world with the initiation of a global phase III study. The company believes that nomlabofusp has the potential to be the first frataxin protein replacement therapy for patients with FA. The stock of Larimar Therapeutics has declined 18.3% so far this year. The consensus estimate for 2025 loss has narrowed from $1.90 per share to $1.89 per share over the past 60 days. The company has a Zacks Rank #2. Zevra Therapeutics: Early adoption of ZVRA's newly approved Miplyffa capsules for treating Niemann-Pick disease type C (NPC) has exceeded the company's expectations. Miplyffa was approved by the FDA in September 2024 as the first treatment for this ultra-rare disease. Zevra plans to file a regulatory application seeking approval of Miplyffa capsules in the EU in the second half of 2025. In April 2025, Zevra sold its Pediatric Rare Disease Priority Review Voucher ("PRV") for gross proceeds of $150 million, which has strengthened its cash position. The stock of Zevra Therapeutics has risen 53.4% so far this year. The earnings estimate for 2025 has risen from 31 cents per share to 76 cents per share over the past 60 days. The company has a Zacks Rank #2. Aldeyra Therapeutics: Burlington, MA-based Aldeyra Therapeutics is a leader in the development of RASP (reactive aldehyde species) modulators for the treatment of immune-mediated disease. Its late-stage pipeline candidates are reproxalap, a RASP modulator for the treatment of signs and symptoms of dry eye disease, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. In June, Aldeyra Therapeutics resubmitted a new drug application (NDA) to the FDA for reproxalap, including data from the Dry Eye Chamber study, which achieved the primary endpoint. The FDA had earlier issued a complete response letter to Aldeyra's NDA for reproxala in April, requiring the company to conduct an additional symptom study for resubmission. Its other product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743 and ADX-631. The stock of Aldeyra Therapeutics has declined 0.4% so far this year. The consensus estimate for 2025 loss has narrowed from $1.03 per share to 90 cents per share over the past 60 days. The company has a Zacks Rank #2. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report Theravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report Larimar Therapeutics, Inc. (LRMR) : Free Stock Analysis Report Zevra Therapeutics, Inc. (ZVRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16-07-2025
- Business
- Yahoo
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Zevra Therapeutics (ZVRA), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Zevra Therapeutics currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> Set to Beat the Market? Let's discuss some of the components of the Momentum Style Score for ZVRA that show why this specialty pharmaceutical company shows promise as a solid momentum pick. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area. For ZVRA, shares are up 28.64% over the past week while the Zacks Medical - Drugs industry is up 1.75% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 45.18% compares favorably with the industry's 1.25% performance as well. Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Zevra Therapeutics have increased 74.97% over the past quarter, and have gained 95.57% in the last year. On the other hand, the S&P 500 has only moved 16.04% and 12.11%, respectively. Investors should also pay attention to ZVRA's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. ZVRA is currently averaging 1,122,698 shares for the last 20 days. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with ZVRA. Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost ZVRA's consensus estimate, increasing from $0.31 to $1.35 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period. Bottom Line Taking into account all of these elements, it should come as no surprise that ZVRA is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Zevra Therapeutics on your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Zevra Therapeutics, Inc. (ZVRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
In a report released on May 27, Jason Butler from Citizens JMP reiterated a Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) with a price target of $19.00. Its fiscal Q1 2025 results, reported on May 15, showed positive operations, with net revenue reaching $20.4 million, driven by product net revenue of $17.2 million. The company beat earnings expectations with a reported EPS of $-0.06, which exceeded the expected $-0.21. A scientist in a lab coat with a microscope magnifying a sample of a rare disease therapy. Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced the closing of the sale of its Pediatric Rare Disease Priority Review Voucher (PRV) on April 7 to an undisclosed buyer, supporting the optimistic sentiment for the stock with gross proceeds of $150 million. The proceeds position the company to strengthen its balance sheet and support development programs and commercial launches. Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a commercial-stage company that develops therapies for rare diseases with limited or no treatment options. Its product portfolio focuses on rare neurological and sleep conditions, including Idiopathic Hypersomnia, Urea Cycle Disorders, and Niemann-Pick disease type C. While we acknowledge the potential of ZVRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZVRA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
